Acorda gains on US Army contract to advance spinal cord treatment
This article was originally published in Scrip
Executive Summary
Shares of Acorda Therapeutics got a 3.4% boost on 24 January on word the company had snagged a $2.67 million research contract from the US Army Medical Research and Material Command (AMRMC) to support the development of the firm's AC105, a magnesium formulation under investigation as a treatment for acute spinal cord injury (SCI).